Glycemicon
Swiss Biotechnology Company
Glycemicon AG is a Swiss biotechnology company developing novel nutraceuticals for the maintenance of normal blood sugar levels and better weight management, using new approaches that were initially developed at the University of Science & Technology ETH Zurich. The lead product’s active substance is a naturally-occurring bile acid, THBA, which drives changes to the body fat architecture that combat elevated blood glucose levels.
GLYCEMICON STANDS FOR "GLYCEMIC CONTROL"
Learn more
THBA - Our lead substance
Glycemicon’s lead substance, THBA, is a type of bile acid that is naturally occurring. It modifies body fat tissue, making it more efficient in decreasing elevated blood sugar levels – a key feature for the maintenance of normal blood sugar levels.
Learn more
Natural products for the maintenance of normal blood sugar levels and better weight management
We combine strong expertise in adipose tissue biology, diabetes and obesity with the top-notch synthetic chemistry of natural products and small molecules. Close interactions with academic collaboration partners, such as the ETH in Zurich, Switzerland, will fuel our pipeline with innovative new approaches and molecules to tackle the epidemic of prediabetes, type 2 diabetes and obesity.
Learn moreNews
Glycemicon Founder Nadja Mrosek Named Female Innovator of the Year
More than 200 women gathered at the Female inn...
View More
